Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04171609 · ClinicalTrials.gov registry record · NA

Expressive Writing for Cancer Survivors

A NA study of Cancer Survivors, sponsored by Duke University.

Completed
Registry status
NA
Development phase
14
Enrollment target
1
Study location

NCT04171609: Completed NA study of Cancer Survivors, sponsored by Duke University.

NCT04171609 is a NA study of Cancer Survivors that has completed, run by Duke University. The registered enrollment target is 14 participants, below the 116-participant average among 11 other Cancer Survivors trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04171609, a NA study of Cancer Survivors, has completed, sponsored by Duke University.

COMPLETED
Registry status
NA
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether a 1-day expressive writing intervention for adult cancer survivors improves resilience scores as measured by the Connor-Davidson Resilience Scale (CD-RISC).

Primary Outcome

This 25-item scale addresses resilience, and has been studied in a variety of populations. Resilience is considered as the capacity to overcome adversity.

Conditions Studied

Interventions

  • BEHAVIORAL Expressive writing

Study Locations (1)

North Carolina

  • Duke Integrative Medicine - Durham

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2019-07-19
Est. Completion 2020-05-14
Phase NA
Duke University

1,725 total trials

What the finished NCT04171609 record still lists

NCT04171609 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 116-participant average among 11 other Cancer Survivors trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Cancer Survivors appearing as the primary indexed condition, and to 1 intervention - of which Expressive writing is the first listed.

NCT04171609 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT04171609 about?

NCT04171609 is a clinical study titled "Expressive Writing for Cancer Survivors". The purpose of this study is to determine whether a 1-day expressive writing intervention for adult cancer survivors improves resilience scores as measured by the Connor-Davidson Resilience Scale (CD-RISC).

What is the current status of trial NCT04171609?

This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2019-07-19. Estimated completion is 2020-05-14.

What conditions does trial NCT04171609 study?

This clinical trial studies the following conditions: Cancer Survivors.

What interventions are being tested in trial NCT04171609?

The interventions under investigation include: Expressive writing (BEHAVIORAL).

Who is sponsoring clinical trial NCT04171609?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04171609 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer Survivors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04171609's enrollment target sits among peer trials

14 11th of 11 higher than 1 of 11 other Cancer Survivors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer Survivors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT04171609, the US trial registry maintained by the National Library of Medicine. NCT04171609 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.